Yaping Chang1,2, Meng Zhu1, Christopher Vannabouathong1, Raman Mundi3,4, Roland S Chou5, Mohit Bhandari1,2,6. 1. OrthoEvidence Inc., Burlington, ON, Canada. 2. Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada. 3. Department of Surgery, University of Toronto, Toronto, ON, Canada. 4. Sunnybrook Holland Orthopaedic and Arthritic Centre, Toronto, ON, Canada. 5. Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. 6. Department of Surgery, McMaster University, Hamilton, ON, Canada.
Abstract
Purpose: Medical cannabis for patients with chronic noncancer pain (CNCP) has been the focus of numerous health care recommendations. We conducted a systematic review to identify and summarize the currently available evidence-based recommendations. Methods: We searched MEDLINE, EMBASE, PsycINFO, the Cochrane database of systematic reviews, and websites for clinical guidelines and recommendations. We summarized the type of the publications, developers, approach of health care recommendation development, year and country of publication, and conditions that were addressed. We categorized the direction and strength of each recommendation. Results: We identified 12 eligible publications. Publication years ranged from 2007 to 2019; four (33.3%) of them were published in 2018. Canada ranked first for the number of publications (n = 4, 33.3%). Most (n = 11, 92%) of the included recommendations were based on both a systematic review of the best evidence and expert consensus. All the included publications provided a recommendation supporting medical cannabis for CNCP in general and for the specific conditions of neuropathic pain, chronic pain in people living with Human Immunodeficiency Virus (HIV), and chronic abdominal pain, with detailed information sharing and comprehensive consideration of a patient's own values and preferences. Conclusion: Clinicians can attend to the guidance currently offered, being aware that only weak recommendations are available for medical cannabis in patients with CNCP, as a third- or fourth-line therapy. Detailed discussions with patients regarding the benefits in reducing pain and potential adverse effects are required before its prescription.
Purpose: Medical cannabis for patients with chronic noncancer pain (CNCP) has been the focus of numerous health care recommendations. We conducted a systematic review to identify and summarize the currently available evidence-based recommendations. Methods: We searched MEDLINE, EMBASE, PsycINFO, the Cochrane database of systematic reviews, and websites for clinical guidelines and recommendations. We summarized the type of the publications, developers, approach of health care recommendation development, year and country of publication, and conditions that were addressed. We categorized the direction and strength of each recommendation. Results: We identified 12 eligible publications. Publication years ranged from 2007 to 2019; four (33.3%) of them were published in 2018. Canada ranked first for the number of publications (n = 4, 33.3%). Most (n = 11, 92%) of the included recommendations were based on both a systematic review of the best evidence and expert consensus. All the included publications provided a recommendation supporting medical cannabis for CNCP in general and for the specific conditions of neuropathic pain, chronic pain in people living with Human Immunodeficiency Virus (HIV), and chronic abdominal pain, with detailed information sharing and comprehensive consideration of a patient's own values and preferences. Conclusion: Clinicians can attend to the guidance currently offered, being aware that only weak recommendations are available for medical cannabis in patients with CNCP, as a third- or fourth-line therapy. Detailed discussions with patients regarding the benefits in reducing pain and potential adverse effects are required before its prescription.
Authors: Gordon H Guyatt; Andrew D Oxman; Regina Kunz; Yngve Falck-Ytter; Gunn E Vist; Alessandro Liberati; Holger J Schünemann Journal: BMJ Date: 2008-05-10
Authors: Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen Journal: JAMA Date: 2015 Jun 23-30 Impact factor: 56.272
Authors: Suzanne Nielsen; Pamela Sabioni; Jose M Trigo; Mark A Ware; Brigid D Betz-Stablein; Bridin Murnion; Nicholas Lintzeris; Kok Eng Khor; Michael Farrell; Andrew Smith; Bernard Le Foll Journal: Neuropsychopharmacology Date: 2017-03-22 Impact factor: 7.853
Authors: Gabrielle Campbell; Wayne D Hall; Amy Peacock; Nicholas Lintzeris; Raimondo Bruno; Briony Larance; Suzanne Nielsen; Milton Cohen; Gary Chan; Richard P Mattick; Fiona Blyth; Marian Shanahan; Timothy Dobbins; Michael Farrell; Louisa Degenhardt Journal: Lancet Public Health Date: 2018-07
Authors: Juan Carlos Acevedo; Abraham Amaya; Oscar de León Casasola; Nelson Chinchilla; Marcelo De Giorgis; Sandra Florez; Miguel Angel Genis; Juan Vicente Gomez-Barrios; John Jairo Hernández; Eduardo Ibarra; Carlos Moreno; Enrique Orrillo; Danilo Pasternak; Sabina Romero; Mariana Vallejo; Maritza Velasco; Alberto Villalobos Journal: J Pain Palliat Care Pharmacother Date: 2009
Authors: Dwight Moulin; Aline Boulanger; A J Clark; Hance Clarke; Thuan Dao; G A Finley; Andrea Furlan; Ian Gilron; Allan Gordon; Patricia K Morley-Forster; Barry J Sessle; Pamela Squire; Jennifer Stinson; Paul Taenzer; Ana Velly; Mark A Ware; Erica L Weinberg; Owen D Williamson Journal: Pain Res Manag Date: 2014 Nov-Dec Impact factor: 3.037
Authors: Kok Yuen Ho; Kok Ann Gwee; Yew Kuang Cheng; Kam Hon Yoon; Hwan Tak Hee; Abdul Razakjr Omar Journal: J Pain Res Date: 2018-09-20 Impact factor: 3.133
Authors: Vânia Meira Siqueira-Campos; Mariana Siqueira Campos de Deus; Omero Benedicto Poli-Neto; Julio Cesar Rosa-E-Silva; José Miguel de Deus; Délio Marques Conde Journal: Int J Womens Health Date: 2022-02-18